- Published at
- by marketscreener.com
neutral
neutral
News for Saniona AB (publ) (0RQJ.L)
- Published at
- by marketscreener.com
positivepositiveSaniona : Auditor's report
Auditors' report in accordance with Chapter 8, Section 54 of the Swedish Companies Act , regarding compliance with the guidelines for remuneration to senior executives approved by the... | May 2, 2023- Published at
- by globenewswire.com
neutralneutralSaniona publishes its interim report for the third quarter of 2022
Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6...- Published at
- by marketscreener.com
negativenegativeSaniona's anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies
PRESS RELEASE November 3, 2022 SAN903 has finalized preclinical development and fulfilled other requirements for clinical developmentPotential first-in-class compound offers a new treatment... | November 3, 2022- Published at
- by marketscreener.com
negativenegativeSaniona extends runway and amends loan agreement with Formue Nord
PRESS RELEASE September 30, 2022 Saniona , a clinical stage biopharmaceutical company, today announced that Saniona and Formue Nord Fokus A/S have agreed to the change the terms of the loan... | September 30, 2022- Published at
- by thestreet.com
negativenegativeSaniona Publishes Its Interim Report For The Third Quarter Of 2021
PRESS RELEASE November 18 , 202 1 Three Months Ended September 30, 2021 (2020) Revenue was SEK 2.3 M (2.2 M)Operating loss was SEK -88.2 M (-37.3- Published at
- by marketscreener.com
mixedmixedSaniona : Notice of extraordinary shareholders' meeting 2021
PRESS RELEASE August 20, 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the... | August 20, 2021- Published at
- by thestreet.com
negativenegativeSaniona Receives U.S. FDA Orphan Drug Designation For Tesomet In Hypothalamic Obesity
PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation- Published at
- by thestreet.com
negativenegativeSaniona Publishes Its Interim Report For The First Quarter Of 2021
PRESS RELEASE May 26 , 202 1 Q1 202 1 ( Q1 20 20 ) Revenue was SEK 3.4 M (2.4 M)Operating loss was SEK -94.1 (-27.4 M)Net profit/loss was SEK -83.4